BioWorld

March 21, 2008

Presidio Gains Early Hepatitis C Program from XTL in $108M Deal

Small antiviral firm Presidio Pharmaceuticals Inc. picked up rights to a group of preclinical small molecules targeting hepatitis C virus in a potential $108 million deal with XTL Biopharmaceuticals Ltd. (BioWorld Today) Read More

Cephalon Gets Much-Anticipated Nod for Treanda in CLL Patients

New Herpes Co-Receptor Found in Research Study

EPIX Cancels Depression Drug Following Phase IIb Failure

PharmAthene Buys Vaccines from Avecia in $40M Deal

Other News To Note

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for Feb. 4, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

MicroRNAs in circulating extracellular vesicles as IPF biomarkers

BioWorld Science

MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...

REST emerges as biomarker in ALS, knockdown improves ALS symptoms

BioWorld Science

About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...